ENDRA Life Sciences (NASDAQ:NDRA) Given New $50.00 Price Target at Ascendiant Capital Markets

ENDRA Life Sciences (NASDAQ:NDRA) had its target price decreased by Ascendiant Capital Markets from $75.00 to $50.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

ENDRA Life Sciences Price Performance

Shares of NASDAQ NDRA opened at $3.67 on Monday. The business has a fifty day moving average price of $4.15 and a 200 day moving average price of $5.55. ENDRA Life Sciences has a 1-year low of $3.02 and a 1-year high of $664.83. The stock has a market capitalization of $2.06 million, a P/E ratio of 0.00 and a beta of 0.19.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Monday, March 31st. The company reported ($9.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.10) by ($5.30). As a group, equities research analysts anticipate that ENDRA Life Sciences will post -47.46 earnings per share for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.